Publication | Closed Access

A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

Radiation OncologyTumor ImmunologyBreast OncologyHer2-overexpressing TumorsBreast Cancer PatientsMedicineImmunologyImmune Checkpoint InhibitorBreast CancerImmunotherapeuticsCancer TreatmentImmunotherapyOncologyCancer TherapeuticsNon-randomized Dose-escalation PhaseHealth Sciences